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Abstract 
Coenzyme Q10 (CoQ10), a benzoquinone present in most organisms, plays an important role in the electron-transport 
chain, and its deficiency is associated with various neuropathies and muscular disorders. CoQ10 is the only lipid-
soluble antioxidant found in humans, and for this, it is gaining popularity in the cosmetic and healthcare industries. 
To meet the growing demand for CoQ10, there has been considerable interest in ways to enhance its production, the 
most effective of which remains microbial fermentation. Previous attempts to increase CoQ10 production to an indus-
trial scale have thus far conformed to the strategies used in typical metabolic engineering endeavors. However, the 
emergence of new tools in the expanding field of synthetic biology has provided a suite of possibilities that extend 
beyond the traditional modes of metabolic engineering. In this review, we cover the various strategies currently 
undertaken to upscale CoQ10 production, and discuss some of the potential novel areas for future research.
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Background
Coenzyme Q, commonly known as ubiquinone or CoQ, 
is a lipid-soluble, powerful antioxidant, and an essential 
cofactor in mitochondrial oxidative phosphorylation [1–
3]. Coenzyme Q is species specific, with differences dic-
tated by the number of isoprenyl units on the isoprenoid 
side chain. For example, 10 isoprenyl units are found in 
human and the fission yeast Schizosaccharomyces pombe 
but fewer units are found in other species (CoQ8 in 
Escherichia coli, CoQ9 in Arabidopsis thaliana, and CoQ6 
in Saccharomyces cerevisiae) [1]. The isoprenoid side 
chain is responsible for the lipid-soluble nature of CoQ, 
whereas its antioxidant capacity derives from its quinone 
head, which can enable electron transfer (Fig. 1). Because 
of this electron-sequestering property, CoQ10 acts as an 
antioxidant at cellular membranes to counteract the oxi-
dation of lipids or lipoproteins [4]. CoQ10 has roles in 
other physiological processes, including sulfide oxidation, 
regulating the mitochondrial permeability transition 
pore, and in the translocation of protons and Ca2+ across 
biological membranes [5, 6]. A detailed account of the 
various aspects of CoQ biosynthesis have been described 
at length elsewhere [1–6].
CoQ10 is the only lipid-soluble antioxidant produced 
by humans, and it localizes to almost every membrane, 
ranging from mitochondrial membranes to that of very 
low density lipoproteins (VLDL) [7]. This solubility 
means that CoQ can protect lipoproteins and lipids from 
peroxidation and oxidative damage [8]. CoQ10 also serves 
alongside other antioxidants, such as vitamins C and E, 
to combat free-radical damage arising from energetic 
mitochondrial reactions [9, 10]. Given its myriad func-
tions and physiological importance, it is not surprising 
that CoQ deficiency can result in numerous diseases.
In model organisms, such as S. cerevisiae and S. pombe, 
CoQ deficiency is not lethal but results in growth defects 
on minimum medium, and a heightened sensitivity to 
oxidative stress [11–15]. In Caenorhabditis elegans, CoQ 
deficiency leads to GABA neuron degeneration, and in 
Drosophila melanogaster, it can cause mitochondrial 
stress and neuronal apoptosis [16, 17]. In humans, CoQ10 
deficiency has been implicated in various diseases involv-
ing muscle and neural development, with the severity of 
the disease correlated with the acuteness of the CoQ10 
shortfall [18]. These diseases may manifest in condi-
tions such as central nervous system (CNS) dysfunction, 
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myopathy or cardiomyopathy, among others [19–22]. The 
oxidative damage associated with impaired CoQ10 func-
tion has also been implicated in numerous clinical phe-
notypes [18, 23–25].
By virtue of its therapeutic relevance, CoQ10 is of par-
ticular importance in the biomedical and health sup-
plement scene. Oral CoQ10 supplements are often 
prescribed alongside treatments for various diseases [26]. 
One example is its co-administration with HMG-CoA 
(3-hydroxy-3-methylglutaryl-coenzyme A) reductase 
(HMGR) inhibitors, widely used cholesterol-lowering 
drugs otherwise known as statins. HMGR catalyzes the 
formation of mevalonic acid, the precursor for choles-
terol and CoQ10 biosyntheses [27]. Patients using statins 
show lower blood levels of CoQ10, and this justifies the 
need for CoQ10 supplementation to reduce the cardio-
myopathy risk associated with statin use [27–30]. The 
presence of CoQ10 is however implicated in resistance 
to chemotherapeutic drugs, and this calls for caution in 
administering CoQ10 alongside certain agents [31, 32].
CoQ10 production decreases with aging [33], as does 
the antioxidant capability of the cell. Increased oxida-
tive stress in aging cells may be ameliorated with dietary 
supplementation of CoQ10 [34]. Indeed, CoQ10 has gar-
nered great popularity as an antioxidant in moisturizers, 
anti-wrinkle and anti-aging skin care treatments [35–37]. 
With the growing demand for skin care cosmetics and 
public awareness of the importance of antioxidants, we 
will likely see an increase in the demand for CoQ10 prod-
ucts on the market quite quickly [38]. Given that CoQ10 
is endogenously synthesized, there should be fewer 
unwanted side effects from its therapeutic use as com-
pared with other synthetic compounds, and this has been 
supported by tolerability studies for high CoQ10 doses 
[39]. Hence, attention has surged in the therapeutic use 
of CoQ10 in non-curable diseases challenging modern 
societies including Alzheimer’s, Huntington’s and Parkin-
son’s, and cardiovascular diseases [40–42].
Industrial production of CoQ10
The range of uses for CoQ10 across the pharmaceutical 
and cosmetics industries has meant that there is great 
commercial interest to scale up the production of CoQ10. 
Frederick Crane first isolated CoQ10 from a bovine 
heart source in the late 1950s [43]. Since then, industrial 
attempts to produce CoQ10 have centered on animal tis-
sue extraction, semi-chemical synthesis, and microbial 
fermentation [44, 45].
The chemical synthesis of CoQ10 has typically involved 
solanesol as a starting substrate and the source of the 
isoprenoid tail, and this is carried out before it is com-
bined with the quinone head [46]. However, as with most 
chemical processes, there are numerous costs associ-
ated with such high-energy catalysis reactions because 
of the need for expensive substrates and because of the 
significant chemical waste generated from its produc-
tion [47–49]. The chemical synthesis of CoQ10 also lacks 
stereoselectivity, and this makes it difficult to separate 
optical isomers to obtain the all-trans biologically viable 
isomer [50].
Owing to these difficulties, microbial biosynthesis has 
become a preferred avenue of CoQ10 production. The 
cell-based catalysis of compounds does not require harsh 
catalytic conditions of heat and pressure that typify many 
chemical synthesis processes. Furthermore, the produc-
tion costs tend to be lower, cheap growth media provides 
an appropriate substrate, and expensive co-substrates can 
be recycled [48, 51]. A living cellular system is also scal-
able, and the precision of the cellular catalytic machinery 
circumvents the problems of stereoselectivity [52, 53]. 
Furthermore, unlike with chemical processing, altered 
genetics does not significantly affect the operating costs, 
meaning that the efforts associated with constructing a 
high-titer-producing organism are worthwhile. Through 
microbial biosynthesis, metabolic engineering approaches 
can be used to increase the titer of CoQ10 and overcome 
some of the limiting steps along the biosynthetic pathway.
Metabolic engineering approaches initially used chemi-
cal mutagenesis-based selection and chemical engineer-
ing procedures that centered on manipulating substrate 
flux; however, the field has since expanded to include 
other strategies from a genetics standpoint [48, 54]. 
The process varies depending on promoter choice and 
strength, cassette copy number, and the localization or 
tethering of enzymes to scaffolds [55, 56]. The choice 
of cassette and promoter are typically host depend-
ent, given that promoter strength and usability rely on a 
species-specific genetic environment and functionality. 
Furthermore, enzymes involved in the tail end of CoQ10 
production are localized in the mitochondria, leading to 
models that propose the involvement of a membrane-
bound complex containing multiple polypeptides of the 
CoQ10 biosynthesis enzymes [57].
Improving flux remains one of the most straightfor-
ward methods to increase yield [48, 58]. Typically, this 
involves finding and circumventing rate-limiting steps in 
Fig. 1 Chemical structure of coenzyme Q10. This molecule consists of 
a isoprenoid side chain composed of ten tandemly linked isoprenyl 
groups attached to a quinone head group
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biochemical pathways and then employing strong pro-
moters to increase the expression of key pathway genes 
to direct biochemical flux. A parallel option entails 
knocking down the expression of genes in alternate path-
ways that branch off the pathway of interest, and this 
can be concomitantly administered, with care taken to 
ensure that these manipulations do not undermine cel-
lular viability and robustness. Alleviating chemical bot-
tlenecks that might hamper the production of the desired 
compound can also be achieved by including genes that 
reconstitute cofactors, such as NADPH and S-adeno-
syl  methionine (SAM). These cofactors play essential 
roles in numerous biochemical pathways [54, 59]. Over-
all, it is clear that close scrutiny and careful optimization 
of biosynthetic pathways can optimize and direct the 
metabolic flux.
Biosynthesis of CoQ10
Entry points to CoQ10 biosynthesis
CoQ biosynthesis involves discrete synthetic stages: pro-
duction of the aromatic group that forms the quinone 
head, production of the isoprene tail, attachment of the 
quinone head to the isoprene tail, and the subsequent 
steps that culminate in the formation of the final CoQ10 
product [1, 60]. In yeast, mitochondria are responsible 
for CoQ synthesis. However, in humans, both mitochon-
dria and Golgi apparatus are proposed sites for CoQ 
synthesis. The chemical precursors for both the quinone 
head and isoprene tail are organism specific. The quinone 
head is derived from the chorismate precursor in the 
shikimate pathway in prokaryotes but from tyrosine in 
higher eukaryotes (Fig. 2). The isoprene tail derives from 
MEP (2-C-methyl-d-erythritol 4-phosphate) in prokary-
otes and plant plastids, which stems from glyceraldehyde 
3-phosphate (G3P), whereas, in eukaryotes, the tail is 
produced from acetyl-CoA in the mevalonate pathway [2, 
61]. These multiple entry points into the pathway could 
be exploited to optimize flux for yield improvement.
The engineering concept of ‘push and pull’ to divert 
metabolic flux implicates that both the inflow and out-
flow reactions must be increased synchronously, other-
wise an accumulation of one product will limit the flux 
and cause an imbalance in the system. Therefore, it is 
crucial to understand the species-specific biosynthetic 
pathways that lead to CoQ10 production. There are sev-
eral biosynthetic pathways of concern, each of which we 
will address separately.
Rate‑limiting steps in biosynthesis of the isoprenoid chain
The first pathway provides the precursors for synthe-
sizing the isoprene tail; if using a prokaryotic system, 
this is achieved through the MEP pathway. The MEP 
pathway starts with the interaction between G3P and 
pyruvate to form 1-deoxy-d-xylulose 5-phosphate (DXP) 
(Fig.  2), which is reported to be the major limiting step 
in the formation of the isoprene tail [62]. Indeed, efforts 
to increase the prokaryotic expression of carotenoids 
(which share the isoprenoid precursor pathway of MEP) 
have focused on improving the first catalytic step of DXP 
formation. Under such contexts, 1-deoxy-d-xylulose-
5-phosphate synthase (DXS) and 1-deoxy-d-xylulose 
5-phosphate reductoisomerase (DXR) are typically over-
expressed to improve the catalytic formation of DXP and 
its subsequent conversion to MEP [60]. These reactions 
eventually yield isopentenyl  diphosphate (IPP), which is 
used to initiate isoprene chain elongation in the isopre-
noid pathway. Similar efforts can be co-opted for the pro-
duction of CoQ [63].
Conversely, in the eukaryotic platform, the mevalonate 
pathway begins with acetyl-CoA and ends with the similar 
production of IPP (Fig. 2). Midway through the pathway 
is the catalysis of HMG-CoA to mevalonate by HMGR, 
the target of statins. Unlike with statins, however, which 
seek to reduce HMGR activity, here aiming to increase 
its activity instead, so as to increase flux to the IPP path-
way. Indeed, the lower Km values of the downstream IPP 
pathway enzymes (farnesyl transferase and geranylgeranyl 
transferase) imply that the enzymatic reactions catalyzed 
(by enzymes including farnesyl and geranylgeranyl trans-
ferases) will reach saturation before that of HMG-CoA [7, 
64]. This concept of exploiting HMGR for increased meta-
bolic production is common; for example, a truncated 
HMGR lacking its inhibitory site can delay enzyme satu-
ration [65, 66]. Regardless of the pathway source, down-
stream signaling leads to IPP and its isomer dimethylallyl 
diphosphate (DMAPP) (Fig. 2). IPP and DMAPP combine 
to form geranyl diphosphate (GPP), and this compound 
is sequentially lengthened by additional IPP moieties to 
form farnesyl diphosphate (FPP), geranylgeranyl diphos-
phate (GGPP), and the subsequent n-isoprene tail [61]. 
Depending on the host organism, components of the 
IPP pathway are also crucial branch points for several 
important compounds, which makes optimization of the 
isoprenoid pathway a lucrative endeavor (and one that 
has been done extensively in S. cerevisiae [59]). GPP can 
branch off and undergo reactions that lead to the forma-
tion of monoterpenoids; FPP, likewise, can form steroids 
and cholesterol; and GGPP can form carotenoids and reti-
noids before decaprenyl diphosphate [1]. Studies suggest 
that inhibiting these various branch points could direct 
metabolic flux from GPP towards decaprenyl diphos-
phate, as seen in FPP yields through the downregulation 
of squalene synthase [67].
CoQ10 production rates are thought to be limited by the 
availability of IPP, since the quinone head is produced from 
the relatively abundant chorismate or tyrosine [68, 69]. 
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However, the tail length of CoQ, which contains varying 
numbers of IPP units, may also be rate-limiting. Although 
CoQ can be produced by multiple microbial platforms, 
each microbe synthesizes CoQ with a characteristic num-
ber of the IPP units. For example, S. cerevisiae and E. coli 
produce CoQ6 and CoQ8, respectively, whereas S. pombe 
and humans naturally produce CoQ10 [60]. Evidence 
shows that polyprenyl diphosphate synthase is the key 
determinant of IPP chain length, as this enzyme catalyzes 
polyisoprenoid tail extension [70]. In comparison, the 
polyprenyl diphosphate:4-HB transferase (UbiA/Coq2), 
which joins the tail and the quinone head, is promiscuous 
in terms of its isoprenoid chain length choice [71]. There-
fore, any attempts to utilize a heterologous, non-native 
host to produce CoQ10 would need to optimize or replace 
the polyprenyl diphosphate synthase to achieve the appro-
priate tail length (10 isoprene subunits). Many groups have 
in fact approached this problem by introducing the deca-
prenyl diphosphate synthase (DPS) gene [72–74].
Rate‑limiting steps in biosynthesis of the aromatic quinone 
group
Another likely avenue to increase metabolic flux is 
through the optimization of the aromatic quinone 
core. The precursor that contributes to the head group 
is 4-hydroxybenzoic acid (PHB or pHBA), which, in 
prokaryotes [60], forms from the condensation of phos-
phoenolpyruvate (PEP) and erythrose-4-phosphate, past 
shikimate, to chorismate and then PHB (Fig.  2) [68]. 
Chorismate is a branch point metabolite necessary in the 
formation of folate and aromatic amino acids (tyrosine 
and phenylalanine) [75]. Thus, it would be advantageous 
to increase the catalytic conversion of chorismate to PHB 
for both proper cell growth and metabolic flux [76].
Earlier work has also shown that CoQ production can 
be increased by the overexpression of chorismate pyru-
vate lyase (UbiC) in E. coli alongside the overexpression 
of several key catalytic enzymes that tend to limit CoQ 
production rates [77]. Similarly, an eightfold increase in 
CoQ10 was reported in the native producer Sporidiobolus 
johnsonii [78]. In other organisms, however, the source 
of PHB differs: mammals produce PHB from tyros-
ine, whereas yeast and plants use both chorismate and 
tyrosine (yeast) or a β-oxidation-like mechanism using 
p-hydroxycinnamic acid (plants) [60, 61]. In these cases, 
the exogenous addition of PHB can increase CoQ10 pro-
duction; albeit, production rates are still reliant on the 
supply of IPP, which is rate-limiting [79, 80].
Rate‑limiting steps in condensation of isoprenoid tail to the 
quinone group
In the final stages, polyprenyl-4-hydroxybenzoate trans-
ferase is required to combine the moieties to form the 
4-hydroxy-3-polyprenylbenzoate precursor [60, 61, 81]. 
The isoprene group varies depending on the species, 
and the ring group undergoes a series of modifications 
(decarboxylation, hydroxylation and methylation) before 
the complete CoQ is synthesized. Flux is primarily deter-
mined by polyprenyl diphosphate transferase, and its 
overexpression in E. coli can generate a 3.4-fold increase 
in CoQ10 production [82]. Conversely, the overexpres-
sion of genes involved in ring modification leads to only a 
minor increase in CoQ10 content in E. coli and S. pombe, 
even if several genes are overexpressed together (in S. 
pombe) [83].
Overall, these findings suggest that the bottleneck in 
CoQ10 production still lies predominantly with IPP flux 
and is then limited by the quinone head formation and 
the required transfer steps [84].
Host platforms employed for CoQ10 production
CoQ10 is only native to a few organisms [2, 81] and it 
remains unknown whether human metabolic reactions 
can cope with a shorter CoQ [85, 86].
Traditionally, most efforts have focused on native 
CoQ10 producers, and screening for mutant strains that 
show higher CoQ10 yields. However, there is great poten-
tial in exploiting heterologous hosts armed with exten-
sive toolbox like E. coli and S. cerevisiae into platforms 
for CoQ10 production. Here, we explore the benefits and 
disadvantages of both native and non-native producers.
Native producers of CoQ10
Native producers have an advantage over heterologous 
hosts, as they do not produce any unwanted CoQ spe-
cies (CoQ8 or CoQ9), which vary by chain length that 
and are specific to the host. The additional costs required 
to extract and separate CoQ10 from other shorter-tailed 
CoQ products may shift the balance in favor of using 
native producers of the enzyme. Indeed, these other, 
(See figure on previous page.) 
Fig. 2 Biosynthesis of coenzyme Q10. Schematic showing the pathway of various metabolic precursors leading to the formation of the quinone 
head (PHB), the isoprene tail (decaprenyl diphosphate), and the final Coenzyme Q product. Reflected in red are the various enzymatic steps that are 
rate limiting. UbiC and UbiA are specific genes from E. coli, and Coq2 is from S. cerevisiae. Unlabelled arrows between chorismate and tyrosine and 
PHB; FPP and decaprenyl diphosphate; and decaprenyl-4-hydrobenzoic acid and coenzyme Q10 denote the presence of multiple steps that have 
been abbreviated
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shorter products will compete for the biochemical flux 
and affect the yield of the desired CoQ10 [60].
Several native producers of CoQ10 have been iden-
tified or optimized as candidates for CoQ10 produc-
tion, including S. pombe, S. johnsonii, Rhodobacter 
sphaeroides and Agrobacterium tumefaciens [78, 83, 87, 
88]. Several other organisms, including Pseudomonas, 
Paracoccus bacteria, Candida and Saitoella yeasts also 
produce CoQ10 natively but have not been sufficiently 
characterized as producing hosts, and many require 
the inclusion of expensive constituents in the growth 
media for proper function. Here, we will explore four of 
the most feasible native hosts for CoQ10 production: (1) 
S. pombe, (2) S. johnsonii, (3) R. sphaeroides and (4) A. 
tumefaciens.
Native producer: Schizosaccharomyces pombe
Schizosaccharomyces pombe (fission yeast) is a well-
studied model organism with similar molecular pathway 
makeup and genetic mechanisms as those in humans 
[89, 90]. However, little effort has been made to develop 
S. pombe into a suitable framework for high-value com-
pound production [91], and so efforts to increase CoQ10 
in S. pombe have thus far been limited. In one study, 
genes encoding enzymes directly involved in CoQ10 bio-
synthesis (dps1+–dlp1+, ppt1+, and coq3+–coq9+) and 
HMGR [83] were overexpressed. However, only over-
expression of HMGR—and not the CoQ10 biosynthesis 
genes—led to a prominent 2.7-fold increase in CoQ10 
yield (Table 1). It was posited that the lack of effect from 
the biosynthetic genes was because these enzymes are 
not rate-limiting.
More success has been attained in the production of 
ricinoleic acid, a fatty acid from castor oil in S. pombe 
[92], and it may be possible to hijack this system to 
co-produce both CoQ10 and fatty acids, with CoQ10 
participating as a lipid-soluble antioxidant to protect 
polyunsaturated fatty acids (PUFA) against oxidative 
damage during storage. A similar approach has been 
explored in Yarrowia lipolytica, an oleaginous yeast, even 
though Y. lipolitica is a non-native producer of CoQ10, 
and this approach is currently undergoing approval for 
production [93]. The approach capitalizes on the same 
IPP pathway to produce carotenoids, and it has been sug-
gested that this may lead to a reduction in flux and the 
generation of alterative products that will include CoQ10. 
Indeed, high CoQ10 selection based on mutant strains of 
Protomonas extorquens and R. sphaeroides are correlated 
with low carotenoid production [94].
Native producer: Sporidiobolus johnsonii
Sporidiobolus johnsonii was recently discovered as a nat-
ural producer of CoQ10 at 0.8–3.3  mg/g dry cell weight 
(DCW) (Table  1), which, in an unmodified strain, sug-
gests a great potential as compared with the current top 
native (A. tumefaciens; 6.92–9.6 mg/g DCW) and heter-
ologous (E. coli; 2.4  mg/g DCW; see below) producers 
[78, 95]. Efforts to use S. johnsonii as a production host 
at an industrial level have achieved 10 mg/g DCW; albeit, 
this yield involved exogenous PHB in the media [78]. 
Other mutagenesis attempts led to a mutant UF16 strain 
with 7.4 mg/g DCW [96].
Native producer: Rhodobacter sphaeroides
Rhodobacter sphaeroides is a photosynthetic bacterium 
[97] initially selected by screening mutant strains based 
on color change, which indicated a reduction in carote-
noid production, and thus, by correlation, an increase in 
CoQ10 [94]. Promoter-based balancing of metabolic flux 
increased the production to 7.16–8.7  mg/g DCW [60, 
98], and a recent study reported production as high as 
12.96 mg/g DCW [87] (Table 1). However, other efforts 
to increase MEP pathway flux did not translate well into 
increased CoQ10 production, probably due to an accumu-
lation of toxic intermediates [99]. R. sphaeroides, how-
ever, is reported to have limited growth rates, even when 
grown in optimal fermentation conditions [84]. This, 
coupled with other difficulties (such as requiring anaero-
bic and light conditions to produce higher CoQ10 titers) 
makes R. sphaeroides a less ideal host choice [100, 101].
Native producer: Agrobacterium tumefaciens
Agrobacterium tumefaciens is a Gram-negative bacte-
rium that is widely used as a transmission vector tool for 
plant genetic modification [102]. Besides R. sphaeroides, 
Table 1 Comparison of yield and methodologies employed in the native producers of coenzyme Q10
Native hosts for coenzyme Q10 production
Host Yield (mg/g DCW) Ref Methodologies
Schizosaccharomyces pombe 1.35 [83, 162] Overexpression of native HMGR gene
Sporidiobolus johnsonii 10 [78] Addition of exogenous HBA
Rhodobacter sphaeroides 12.96 [87] Overexpression of multiple MEP pathway genes coupled with fine-tune of quinone 
modification pathway genes
Agrobacterium tumefaciens 6.92 [83, 163] Ectopic expression of DXS and DPS genes in optimized media
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it is one of the top producers of CoQ10 at 6.92–9.6 mg/g 
DCW [61, 83] (Table  1). Initial attempts to increase its 
production yield involved selecting cells based on their 
growth on inhibitory precursor analogues [103]. Later 
efforts involved targeting the overexpression of IPP path-
way genes, especially DXS [60]. A. tumefaciens, however, 
produces unwanted exopolysaccharides, which increases 
the viscosity of the sample and affects CoQ extraction 
[88, 104].
Issues with native hosts
Native producers initially have higher CoQ10 yields as 
compared with non-native producers. However, few, if any, 
of the biosynthetic pathways leading to CoQ10 production 
have been optimized in these organisms, and the toolbox 
of promoters and genetic modules needed for effective 
tuning of native producers is lacking [84, 98]. Neither A. 
tumefaciens nor R. sphaeroides produce sufficient quanti-
ties of CoQ10 to meet current market demands, and this 
has led to higher prices of CoQ10 [38]. Furthermore, rather 
than optimizing the hosts, recent efforts in the field have 
been to develop toolkit pieces, such as promoter-regulated 
vectors [98, 99], or to determine ways to select for particu-
lar strains after mutagenesis [105]; only a few studies have 
attempted to harness metabolic engineering (to increase 
gene expression) or protein engineering [83, 87]. Other 
efforts garnered toward a more immediate solution have 
had to rely on the addition of precursors to increase yield, 
and this comes at a higher cost and therefore remains less 
feasible [106, 107].
Heterologous hosts
One method to circumvent the shortfalls seen with native 
producers is to use a heterologous platform that hosts 
high pliability towards genetic manipulation [108]. Het-
erologous systems are often avoided because of the pro-
duction of unwanted CoQ species, the lengths of which 
are influenced by the chain length of the host organism 
and the nature of the heterologous polyprenyl diphos-
phate synthase; this is particularly complicated, as the 
synthases may function as either homo or hetero-dimers 
[109]. However, organisms that possess a large toolkit for 
host engineering are desirable, and their use holds prom-
ise to overcome some of the limitations seen with native 
hosts, assuming that these species can be appropriately 
optimized to produce CoQ with the correct chain length. 
In light of this, here, we explore two options—E. coli for 
prokaryotes and S. cerevisiae for eukaryotes [108]—as 
well as the utility of plants as heterologous hosts.
Heterologous host: Escherichia coli
The success in engineering E. coli to produce human 
insulin paved the way for a new frontier in metabolic 
engineering [110]. E. coli grows fast and is cheap to 
culture, and the large range of molecular tools, coupled 
with an extensive knowledge of its genetic, cellular and 
metabolic profiles, makes it a widely used production 
platform. Indeed, most compounds produced by meta-
bolic engineering of E. coli command a good chance of 
success [108, 111, 112]. Hence, it is not surprising that 
strategies developed and optimized for the metabolite 
production in E. coli can be exploited for the production 
of CoQ10. However, E. coli natively produces CoQ8 not 
CoQ10 [77], and efforts to produce CoQ10 involved the 
addition of DPS from a native producer (A. tumefaciens 
or G. suboxydans) [113, 114]. Yet, despite producing 
CoQ10, the bacteria also produced CoQ products of vari-
able tail lengths (CoQ8 and CoQ9) [115]. This was solved 
by knocking out the octaprenyl diphosphate synthase 
(IspB), which led to a minimal production of the other 
CoQ variants [116]. Other efforts used a DPS of greater 
stringency, and found that DPS from R. sphaeroides was 
more discerning in producing CoQ10 than DPS from A. 
tumefaciens [115].
Methods to improve the titer of CoQ10 in E. coli sought 
to increase the flux from the MEP pathway toward IPP 
[94, 116], while others reconstructed the complete meva-
lonate pathway to divert flux without encountering inter-
ference from negative regulators, such as HMGR by FPP 
in its native context [117, 118]. Although this reconstruc-
tion successfully increased CoQ10 yield, there was a met-
abolic bottleneck at the top end of the pathway involving 
mevalonate conversion (Fig. 2). When the lower part of 
the pathway was ectopically expressed, a twofold increase 
in yield was observed; yet, expression of the entire path-
way led to only a 1.5-fold increase.
Several metabolomic studies in E. coli have investigated 
the rate-limiting steps in CoQ10 production [68, 119] by 
adding in the precursors exogenously to decouple the 
pathway away from cellular flux production. Not surpris-
ingly, both the isoprenoid tail and aromatic quinone head 
are rate-limiting in E. coli [68, 120–122]. Yet, when these 
two precursors are no longer limiting, the downstream 
genes involved in ring modification (ubiB, ubiH and ubiG) 
becomes limiting [68]. In an effort to increase flux to the 
quinone precursor PHB, another study overexpressed 
chorismate pathway genes, including the gene encoding 
for 3-deoxy-d-arabinoheptulosonate 7-phosphate syn-
thase, which initiates the first step in combining PEP with 
d-erythrose 4-phosphate [122] (Fig. 2). However, despite 
these efforts, CoQ10 levels in E. coli (0.45–3.63  mg/g 
DCW) still fall short of the levels produced by native pro-
ducers (R. sphaeroides and A. tumefaciens) [99] (Table 2).
Heterologous host: Saccharomyces cerevisiae
Another popular host in metabolic engineering efforts 
is the budding yeast, Saccharomyces cerevisiae. As a 
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model organism, the genome of S. cerevisiae has been 
extensively studied and modified, and there are many 
already optimized tools for efficient gene expression and 
genetic building blocks for promoters and other regula-
tory elements [123, 124]. S. cerevisiae has a fast growth 
cycle of about 90 min, and has a high cultivable density 
as compared with bacteria. The budding yeast can also 
perform homologous recombination and compartmen-
talize subcellular processes, making it an excellent host 
for metabolic engineering purposes. It is also a ‘Gen-
erally Recognized As Safe’ (GRAS) organism (United 
States Food and Drug Administration) (Table 2), and this 
reduces any potential complications that could arise from 
its use in the production of a health supplement or a 
nutritional product [56]. Most importantly, the IPP path-
way has been extensively optimized in S. cerevisiae [59].
Unfortunately, similar to E. coli, S. cerevisiae natively 
produces CoQ6 not CoQ10 [1]. Early attempts to delete 
the COQ1 gene in S. cerevisiae and replace it with DPS 
from G. suboxydans under the COQ1 promoter report-
edly yielded 12.3 µg/g DCW [85]. However, DPS tends to 
require a heterodimer formation for proper function and, 
when expressed, may instead form dimers with native 
polyprenyl diphosphate synthases to produce products of 
differing lengths [125] (Table 2). An alternative approach 
would be to examine the functionality of the DPS enzyme 
by fine-tuning is length-determining function. This would 
be advantageous on several levels, given that the DPS 
reaction is a limiting step in CoQ10 production. Indeed, 
polyprenyl diphosphate synthase belongs to the protein 
family of prenyl-synthases, many of which are involved 
in generating the polyisoprenoid chain components of 
commercially interesting compounds like alkaloids and 
monoterpenes [7, 68]. If successful, this will conceptu-
ally sidestep the aforementioned problem of homodi-
merization of overexpressed heterologous DPS. We thus 
propose that an understanding of the mechanism by 
which polyprenyl diphosphate synthase determines chain 
length may allow for the production of CoQ10 in S. cerevi-
siae without generating off-target products.
Heterologous host: plants
Another suggested strategy for CoQ10 production is the 
use of plant hosts for the ease of CoQ10 supplementa-
tion into the diet [38]. Such efforts are currently under-
way, in conjunction with other nutritional supplements, 
such as vitamin A (beta-carotene) in ‘golden rice’ (Oryza 
sativa), which can be likewise co-opted in the context of 
CoQ10 given that carotenoid production also employs 
the IPP pathway [38, 126]. However, the political has-
sle associated with the commercialization of ‘golden 
rice’ or other genetically modified foods is expected to 
be a counter-rationale for the biosynthesis of CoQ10 in 
plant hosts [127–130]. Furthermore, because CoQ10 is 
also prescribed for deficiency-associated diseases and 
as an ingredient in various cosmetics, it must be prop-
erly extracted. Plant production hosts also have further 
technical obstacles, such as difficulties in engineering 
and manipulating the plant host; the need for large plots 
of expensive, arable land; a dependency on harvesting 
time; and the risk of unpredictable climate conditions 
in sync with market demand. It is for these various rea-
sons that plant hosts are not deemed economically viable 
for CoQ10 production. These challenges, along with the 
comparatively less effort in the scientific community to 
exploit plant hosts, has meant that microbial hosts are a 
better choice for CoQ10 production [131].
Potential future engineering approaches for CoQ10 
production
There have been frequent attempts to engineer key 
enzymes within the CoQ10 pathway to increase the 
yield, including attempts to regulate IPP chain length. 
Recent interest in synthetic biology—which involves 
the fine-tuning of biosynthetic processes by controlling 
the genome and global organellar organization—prom-
ises to further revolutionize traditional bioengineering 
approaches. Several of the newly innovated methodolo-
gies will be discussed in the context of improving CoQ10 
biosynthesis in the following sections.
Decaprenyl diphosphate synthase
In essence, there are two ways to induce a non-native 
heterologous host to make CoQ10: (1) Engineer the poly-
prenyl diphosphate synthase—which is solely responsible 
for chain length—to assume the function of DPS, or (2) 
introduce a DPS into the host and delete the native poly-
prenyl diphosphate synthase. The latter is based on ear-
lier reports, where CoQ of differing tail lengths have been 
produced by heterologous hosts [2, 15, 71, 74]. Specifi-
cally, the introduction of ddsA and sdsA into E. coli from 
G. suboxydans and Rhodobacter capsulatus, respectively, 
can result in the formation of CoQ10 (and also CoQ9) 
[74, 113, 132]. PHB-polyprenyl diphosphate transferase 
(COQ2) lacks the specificity of polyprenyl diphosphate 
synthase, as it is able to transfer isoprenoid tails of vary-
ing length; e.g., E coli UbiA can utilize isoprenoid chains 
of 5–10 residues in length. Based on this promiscuity, the 
PHB:polyprenyl diphosphate transferase is expected not 
to be a limiting factor in engineering a non-native host 
for the production of CoQ10.
However, engineering a heterologous host via the 
introduction of exogenous DPS suffers from challenges 
that cannot, as yet, be explained. Even with the efforts 
of removing endogenous CoQ production by delet-
ing the native polyprenyl diphosphate synthase gene, 
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there remains a lack of stringency in these reactions. 
For example, when the DPS gene from G. suboxydans is 
expressed in E. coli, deletion of the native IspB gene only 
reduces the production of CoQ8 and CoQ9; even though 
it still predominantly produces CoQ10 [74, 113]. A fur-
ther complication to the engineering effort lies with 
the complex formation of polyprenyl diphosphate syn-
thases, which function as homodimers (IspB in E. coli, 
Coq1 protein in S. cerevisiae, and DdsA in G. suboxy-
dans) or heterotetramers (Dps1-Dlp1 in S. pombe and 
HsPDSS1-HsPDSS2 in humans) [133, 134]. For instance, 
when heterologously expressed in E. coli, COQ1 from S. 
cerevisiae can replace IspB, an otherwise essential gene 
for the production of CoQ6 [70, 132]. However, when 
COQ1 from S. cerevisiae is expressed in Dlp1-deficient 
S. pombe, it rescues the dlp1 deletion by forming a het-
erodimer with Dps1 to produce CoQ10 [131]. Similarly, 
Dps1 or Dlp1 in S. pombe can complex with defective 
IspB mutants to restore functionality in E. coli [135]. In 
such cases, heterologous expression of DPS creates arti-
ficial interactions with the host DPS, calling for caution 
in considering CoQ10 production through host chassis 
engineering.
Polyprenyl diphosphate synthase residue functionality
Polyprenyl diphosphate synthases catalyze the formation 
of the polyprenoid tail by adding IPP units to an allylic 
diphosphate base [136]. These enzymes are categorized 
depending on the final carbon chain length of the syn-
thesized product: class I for C10–20, class II for C30–35, 
class III for C40–50, and class IV for even longer prod-
ucts [115]. Class IV synthases also catalyze some cis-
configuration double bonds, whereas the other classes all 
catalyze trans-configuration bonds. Synthases from class 
II and III categories should be chosen when studying tail 
length determination because these classes reflect both 
the final carbon chain length product and possess a simi-
lar stereo configuration of double bonds to that of DPS, 
with an average homology of 30–50% between the poly-
prenyl diphosphate synthases and DPS enzymes [113, 
133].
There are seven conserved regions within trans-type 
prenyltransferases, two of which (domain II and VI) pos-
sess a DDXXD motif [71, 137]. These motifs are located 
in two helices that face each other, and are the binding 
sites for FPP (Helix D) and IPP (Helix H) with the aid of 
Mg2+ in substrate binding [136, 137] (Fig.  3a). The fifth 
residue before the DDXXD motif in domain II deter-
mines tail chain length. In GGPP and FPP (Thermo-
plasma), this residue is Tyr-89, a large bulky residue; in 
OPP (Thermotoga maritime) and IspB (E. coli), it is Ala-
76 and Ala-79, respectively. These amino acid differ-
ences are associated with an inverse relationship between 
residue size and chain length [136]. Indeed, when Ala-76 
and Ala-79 are changed to Tyr, the product chain length 
decreases from C40 to C20 [136]. In another study, this 
same substitution (in E. coli) in the absence of wild-type 
IspB, produces a non-functional protein, but one that is 
still able to heterodimerize with the wild-type protein to 
produce CoQ6 [71].
Elongation of the polyprenyl chain takes place in a ‘tun-
nel’ between helices H and D, where A76 (in T. mari-
time) lies at one end near the DDXXD motif and Phe-132 
(Met-135 in E. coli) lies at the other end; this Phe resi-
due is thought to serve as a cap-like residue [136, 138]. 
Mutating Phe-132 to Ala can increase the chain length 
from C40 to C50, which suggests a method to increase 
chain length synthesis by polyprenyl diphosphate syn-
thases. This was confirmed by others, who, using a cis-
type prenyltransferase, found that substituting leucine 
for alanine increased the chain length from C55 to C70 
[139]. In addition to Met-135 in E. coli, another residue, 
Met-123, compositely serves to limit the elongation of 
the IPP chain; hence, Met-123 and Met-135 are proposed 
to contribute to a ‘double-floor’ (‘floor’ is synonymous 
with ‘barrier’), as opposed to the ‘single-floor’ created by 
Phe-132 in T. maritime [138].
Efforts to engineer the polyprenyl diphosphate syn-
thases in a host that is highly malleable to genetic and 
metabolic engineering, such as S. cerevisiae, may pro-
vide a prospective avenue to increase the yield of CoQ10. 
A sequence alignment of polyprenyl diphosphate syn-
thases from various organisms shows high similarity 
at the amino acid level in the helices that constitute the 
chain elongation tunnel (Fig. 3b). Such high conservation 
means that functional studies conducted with T. mari-
time polyprenyl diphosphate synthases could serve as a 
reference to guide engineering efforts in other species, 
such as COQ1 from S. cerevisiae.
Spatial metabolic organization with synthetic 
compartmentalization
Metabolic production of CoQ10 may also be increased by 
manipulating the spatial organization of the enzymes in 
the cell. This is particularly important when faced with 
potential off-target reactions or when the accumulation 
of products results in toxicity [140–142]; albeit, clinical 
studies indicate that toxicity from CoQ10 supplementa-
tion is not a huge concern [29].
Some of the more common ways to recruit the path-
way into a localized complex involves the use of protein 
scaffolds or linkers to tether the pathway enzymes to pro-
teins of interest [143–147]. This manipulation concen-
trates the substrate close to the enzyme, and may favor 
the forward metabolic flux, as an intermediary metabo-
lite may be captured and shunted into the next step of the 
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pathway. Conceptually, such spatial arrangement reduces 
the emergence of unwanted by-products, especially with 
more promiscuous enzymes.
When stoichiometric ratios of sequential reactions are 
of relevance, tethering also helps to modulate the ratio 
of enzyme to protein [56]. However, tethering may cause 
rigidity in the protein scaffold or direct enzyme fusions 
that could affect enzymatic function. However, these 
issues can be overcome with the use of a linker sequence, 
which provides increased flexibility to orientate the 
direction of the reaction and lower the risk of potential 
disruptions to enzyme folding.
Fig. 3 a Protein homology modeling of COQ1 (YBR003W) was performed using ModBase [159] and was viewed using Swiss PDB Viewer [160]. 
The template for modeling was based on the medium/long-chain length prenyl pyrophosphate synthase of Arabidopsis thaliana (3aq0A) with 42% 
sequence identity. Helix D and Helix H bind to the elongating isoprene chain and IPP, respectively, at the conserved DDXXD regions. Helix F contains 
Met-244 and Helix E contains Ser-231, which are thought to be the residues that regulate chain length elongation. The right figure represents the 
180° view of that on the left and is superimposed with the structure of CoQ10. b Multiple sequence alignment of Q9X1M1_THEMA (T. maritime 
TM_1535), ISPB_ECOLI (E. coli IspB), COQ1_SCEREVISIAE (S. cerevisiae COQ1), DPS1_SPOMBE (S. pombe Dps1) and DPS1_HSAPIENS (Human PDSS1) 
using CLUSTAL W [161]. Helices D (grey), E (green), F (blue), and H (white) indicated in (a), are boxed in (b). Orange underline marks the DDXXD motif. 
Red asterisks indicate the positions of S. cerevisiae COQ1 Met-244, Ser-247 and Ser-231 residues. Met-244 corresponds to Leu-188 and Leu-231, and 
Ser-247 to Val-191 and Val-234 of S. pombe Dps1 and H. sapiens PDSS1, respectively. Labels of helices are marked with the same colors as those used 
for the helices in a
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In lieu of scaffold or linker systems, synthetic subcel-
lular compartmentalization can also be used, whereby 
the enzyme complex is targeted to protein shells or orga-
nelles (Fig.  4). This would further reduce any unwanted 
side-effects or steric problems, which likely occur on 
protein scaffolding. The use of such synthetic compart-
mentalization may also sequester any toxic products 
produced by the reaction and preserve cell viability. One 
potential pathway for the ectopic induction of compart-
mentalization is through the use of bacterial micro-
compartments—proteinaceous organelles derived from 
prokaryotes [148–151]. These synthetic organelles pos-
sess selectively permeable surfaces comprising thou-
sands of shell proteins and can sequester the enzymatic 
pathways by means of N-terminal targeting sequences to 
link the enzymes to the surface of the organelle. Carbox-
ysomes are one example of a bacterial microcompartment 
that contains ribulose-1,5-bisphosphate carboxylase oxy-
genase (RuBisCO) for carbon-fixing activities [152–154]. 
In eukaryotes, protein-based compartments (which com-
prise ribonucleoprotein particles) known as ‘vaults’, can 
also be used; albeit, less is known about the structure and 
mode of formation of these compartments [155, 156]. 
Finally, it may be simpler to target the eukaryotic orga-
nelle pathways that already exist; for instance, one group 
sought to increase opioid production by altering the 
pathway of proteins to the endoplasmic reticulum (ER) 
by ER-tagging of the relevant enzymes. This modification 
increased the titer and specificity of the product of inter-
est [157].
In cases where modifications are made to the pre-
combined quinone head and isoprene tail, the enzymes 
required are already localized in the mitochondria in a 









: Direction of biochemical Flux
E1 ~ E6 Enzymes along biosynthetic pathway:
Microbial cell
E1 E2 E3 E4 E5 E6
Fig. 4 Spatial metabolic organization with synthetic compartmentalization. Diagrammatic representation of a synthetic proteinaceous or nanotube 
micro-compartmentalized organelle can be engineered in microbial cells [149–151]. The organelle consists of a scaffold on which the biosynthetic 
enzymes can be immobilized to direct the biochemical flux such that the substrate of an enzyme is the product of another juxtaposed enzyme. 
Toxic byproducts may conceptually be shunt into sub-compartments within the organelle and sequester therein to ensure optimal growth of the 
microbial host
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membrane (prokaryotes); although, there is, as yet, no 
evidence for a complex in prokaryotes [11, 158]. How-
ever, the other pathways involved in generating the pre-
cursor head and which lack bio-orthogonal chemistry are 
still candidates for spatial organization; for example, the 
mevalonate pathway, which leads to the IPP precursor, 
could be one option. Indeed, SH3 ligands and domains 
are used to link HMG-CoA synthase with HMGR to pre-
vent the accumulation of HMG-CoA and reduce its asso-
ciated cytotoxicity [143].
Chorismate could be another option. As mentioned 
earlier, chorismate is a branch point metabolite and thus 
its recruitment could be spatially separated so as to pre-
vent its conversion into off-target aromatic amino acids. 
This segregation would be advantageous, as this pathway 
is essential and cannot be completely disrupted. If a plant 
platform were to be used, attention would have to be 
given to the alternate and possibly competing products 
of GPP, FPP and GGPP. In non-native hosts, CoQ prod-
ucts will present with a range of tail lengths because of 
the use of the promiscuously inserted decaprenyl diphos-
phate synthase and its interactions with host polyprenyl 
diphosphate transferase. These are some possible can-
didate biosynthesis modules that may benefit from the 
manipulation of spatial organization and can be opti-
mized in future experiments.
Conclusions
CoQ10 is a valuable and commercially important prod-
uct that has yet to be produced to a level that can sup-
port market demands. This review gives an overview 
of the native and heterologous hosts reported thus far 
for the production of CoQ10. Currently Rhodobacter 
sphaeroides triumphed as the native host in producing 
12.96  mg/g DCW of CoQ10. On the other hand, the 
most widely used workhorse for industrial produc-
tion of valuable compounds—E. coli—only achieved 
3.63 mg/g DCW as the most productive of the heterolo-
gous hosts by far. Thus, use of native hosts still remains 
as the best option for industrial scale production of 
CoQ10. However, with new tools and progress made in 
recent years with the advent of synthetic biology, CoQ10 
production may stand a chance to be revolutionized. 
It will be exciting to expect future new technological 
breakthroughs in this field to take production to new 
levels either in native or heterologous producers.
Abbreviations
CoQ: coenzyme Q; CoQ10: coenzyme Q with chain containing 10 isoprene 
subunits; VLDL: very low density lipoproteins; CNS: central nervous system; 
PDSS1: prenyl diphosphate synthase, subunit 1; HMG-CoA: 3-hydroxy-3-meth-
ylglutaryl-coenzyme A; SAM: s-adenosyl methionine; MEP: 2-C-methyl-d-eryth-
ritol 4-phosphate; G3P: glyceraldehyde 3-phosphate; DXP: 1-deoxy-d-xylulose 
5-phosphate; DXS: 1-deoxy-d-xylulose-5-phosphate synthase; DXR: 1-deoxy-
d-xylulose 5-phosphate reductoisomerase; IPP: isopentenyl diphosphate; 
HMGR: HMG-CoA reductase; DMAPP: dimethylallyl diphosphate; GPP: geranyl 
disphosphate; FPP: farnesyl diphosphate; GGPP: geranylgeranyl diphosphate; 
DPS: decaprenyl diphosphate synthase; PHB or pHBA: 4-hydroxybenzoic aid; 
PEP: phosphoenolpyruvate; DCW: dry cell weight; GRAS: generally recognized 
as safe; RuBisCO: ribulose-1,5-bisphosphate carboxylase/oxygenase.
Authors’ contributions
SLQE, MK, and ESC wrote the manuscript; TST performed COQ1 modeling; ESC 
coordinated the work. All authors read and approved the final manuscript.
Author details
1 Department of Biochemistry, National University of Singapore, Singapore, 
Singapore. 2 National University Health System (NUHS), Singapore, Singapore. 
3 NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), 
Life Sciences Institute, National University of Singapore, Singapore, Singapore. 
4 NUS Graduate School for Integrative Sciences and Engineering, National 
University of Singapore, Singapore, Singapore. 5 School of Chemical & Life Sci-
ences, Nanyang Polytechnic, Singapore, Singapore. 6 Faculty of Life and Envi-
ronmental Science, Shimane University, Matsue 690-8504, Japan. 
Table 2 Comparison of yield, benefits and limitations in the heterologous producers of coenzyme Q10
Host Bacteria (E. coli) Yeast (S. cerevisiae) Plants
Yield 0.45–3.63 mg/g DCW 12.3 µg/g DCW Not used
Suitability for human consumption No Generally recognized as safe 
(GRAS)
Yes
Produced CoQ10 proposed to serve 
as direct dietary supplement
Fast growth Yes Yes No
Dependency on harvesting time
Extensive knowledge and tool-kit available for 
genetic, metabolic, protein engineering
Yes Yes No
Cultivation/culture density High High Low
Require large plot of arable land
Mixed chain length products produced and 
increase cost of purification of CoQ10
Yes Yes Yes
Inability to sidestep metabolic bottlenecks to 
induce high production level
Yes Yes Yes
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